Louisiana 2018 Regular Session

Louisiana Senate Bill SB134

Introduced
2/27/18  
Introduced
2/27/18  
Refer
2/27/18  
Refer
2/27/18  
Refer
3/12/18  
Refer
3/12/18  
Report Pass
3/14/18  
Report Pass
3/14/18  
Engrossed
3/19/18  
Engrossed
3/19/18  
Refer
3/20/18  
Refer
3/20/18  
Report Pass
4/12/18  
Report Pass
4/12/18  
Enrolled
5/1/18  
Enrolled
5/1/18  
Chaptered
5/10/18  
Chaptered
5/10/18  
Passed
5/10/18  

Caption

Provides relative to prescriptions for controlled dangerous substances. (8/1/18)

Impact

The passing of SB 134 will influence how prescriptions are managed in Louisiana, particularly with Schedule II drugs, which are typically subject to strict regulations due to their potential for abuse. This legislative change is expected to improve patient access to necessary medications while encouraging responsible use and compliance with prescription guidelines. Additionally, it may relieve pressure on both patients and pharmacists by simplifying the dispensing process under certain circumstances.

Summary

Senate Bill 134, introduced by Senator Mills, addresses the dispensing protocols for controlled dangerous substances, specifically Schedule II drugs. The bill allows for the option for patients to receive a lesser quantity of medication than what was originally prescribed by a medical practitioner. This amendment aims to offer flexibility for patients who may not require the full amount of a prescribed drug at any given time, enhancing patient-centered care and potentially reducing waste.

Sentiment

The general sentiment surrounding SB 134 appears positive, as it prioritizes patient needs and offers a pragmatic approach to prescription management. The bill received unanimous support in the House with a vote of 85 in favor and no opposition, indicating a broad consensus among legislators about its importance and potential benefits. This strong backing suggests that the bill aligns with current healthcare goals of flexibility and patient-focused solutions.

Contention

Despite the positive reception, some concerns may arise regarding the implications of reducing prescribed quantities. It is crucial to monitor the impact of the bill on patient health and safety to ensure that it does not inadvertently result in inadequate treatment for individuals who may require extended prescriptions. Additionally, the ability for pharmacies to adopt these changes seamlessly poses a logistical challenge that may need further oversight.

Companion Bills

No companion bills found.

Similar Bills

CA AB2789

Health care practitioners: prescriptions: electronic data transmission.

CA AB852

Health care practitioners: electronic prescriptions.

CA AB149

Controlled substances: prescriptions.

TX SB594

Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2766

Relating to electronic and other controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.